Whole Group (n = 72) | AKT positive (n = 31) | AKT negative (n = 41) | p value | MAPK positive (n = 32) | MAPK Negative (n = 40) | p value | |
---|---|---|---|---|---|---|---|
Age (range) | 65 (36–80) | 67 (41–80) | 65 (36–78) | ns | 65 (38–80) | 66 (40–79) | ns |
Sex | |||||||
Males | 51 (70%) | 20 (65%) | 31 (65%) | ns | 23 (72%) | 28 (70) | ns |
Females | 21 (30%) | 11 (35%) | 10 (35%) | ns | 9 (28%) | 12 (30%) | ns |
ECOG PS | |||||||
0–1 | 58 (81%) | 27 (87%) | 31 (76%) | ns | 29 (90%) | 29 (72%) | ns |
2–3 | 14 (19%) | 4 (13%) | 10 (23%) | ns | 3 (10%) | 11 (28%) | ns |
Metastatic sites | |||||||
1 | 21 (30%) | 8 (26%) | 13 (32%) | ns | 10 (32%) | 11 (27%) | ns |
≥ 2 | 51 (70%) | 23 (74%) | 28 (68%) | ns | 22 (68%) | 29 (73%) | ns |
Previous lines of treatment | |||||||
1 | 10 (14%) | 4 (13%) | 6 (15%) | ns | 3 (9%) | 7 (17%) | ns |
≥ 2 | 62 (86%) | 27 (87%) | 35 (85%) | ns | 29 (91%) | 33 (83%) | ns |
Treatment | |||||||
mFOLFIRI + Cetuximab | 28 (39%) | 10 (32%) | 18 (44%) | ns | 12 (37%) | 16 (40%) | ns |
Irinotecan + Cetuximab | 44 (61%) | 21 (68%) | 23 (56%) | ns | 20 (63%) | 24 (60%) | ns |
Response Rate | |||||||
PR | 21 (29%) | 5 (16%) | 16 (39%) | ns | 9 (28%) | 12 (30%) | ns |
SD | 19 (26%) | 8 (26%) | 11 (27%) | ns | 7 (22%) | 9 (22%) | ns |
PD | 32 (45%) | 18 (58%) | 14 (34%) | ns | 16 (50%) | 19 (48%) | ns |
Survival | |||||||
m PFS (months) | 3.2 | 2.4 | 6.5 | 0.0006 | 3 | 6 | ns |
m OS (months) | 17.7 | 7.8 | 26.7 | <0.0001 | 11.2 | 26.2 | ns |